COV2-2050
An anti-RBD (SARS-CoV-2 Spike) human monoclonal antibody.
General information
COV2-2050 is a human monoclonal antibody identified in serum of a COVID-19 convalescent patient. It bound SARS-CoV-2 Spike RBD and neutralized the live virus in vitro (Zost et al., 2020a). The antibody prevented weight loss, decreased viral burden, and reduced lung inflammation in a mouse and a hamster model after a viral challenge. The Fc region of the antibody was demonstrated to be important for the therapeutic effect (Winkler et al., 2021).
Supporting references
Link | Tested on | Impact factor | Notes | Publication date |
---|---|---|---|---|
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
Spike protein Animal model In vitro Antibody |
in vitro binding assay; Vero E6 cells; K18-hACE c57BL/6J mice; Syrian hamsters; SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020 | 38.64 | The antibody prevented weight loss, decreased viral burden, and reduced lung inflammation in a mouse and a hamster model after a viral challenge. The Fc region of the antibody was demonstrated to be important for the therapeutic effect. |
Feb/12/2021 |
Potently neutralizing and protective human antibodies against SARS-CoV-2
Spike protein ACE2 Biophysical assay Animal model In vitro Antibody |
in vitro binding assay; in vitro biophysical assay; Vero E6 cells; BALB/c mice; rhesus macaques; SARS-CoV-2 pseudovirus; SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2023 | 42.78 | The antibody neutralized SARS-CoV-2 live virus in vitro. |
Jul/15/2020 |
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
Spike protein Novel compound Protein factor In vitro Antibody |
Patient sera; Vero E6 cell; (VSV) SARS-CoV-2 Spike-pseudotyped virus; SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 | 53.44 | The antibody neutralized SARS-CoV-2 in vitro. |
Jul/10/2020 |